clinical trial · NCT05867030
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.·phase1·withdrawn
Follicular Lymphomalenalidomiderituximabparsaclisib
brief summary
A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
started
Jul 28, 2023
primary completion
Aug 31, 2029
completion
Apr 30, 2033
last updated
Oct 17, 2023
official title
A Phase Ib/III Study to Evaluating the Efficacy and Safety of Parsaclisib in Combination With Rituximab and Lenalidomide Versus Rituximab in Combination With Lenalidomide in Subjects With Relapsed or Refractory Follicular Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol